Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

References

• AmadoRGWolfMPeetersM2008Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2616263418316791
   PubMed Web of Science ®Google Scholar
• BarberTDVogelsteinBKinzlerKW2004Somatic mutations of EGFR in colorectal cancers and glioblastomasN Engl J Med351288315625347
   PubMed Web of Science ®Google Scholar
• BaselgaJMendelsohnJ1997Type I receptor tyrosine kinases as targets for therapy in breast cancerJ Mammary Gland Biol Neoplasia21657410882302
   PubMed Web of Science ®Google Scholar
• BaselgaJ2001Targeting the epidermal growth factor receptor: a clinical realityJ Clin Oncol1941S4S11560970
   PubMed Web of Science ®Google Scholar
• BerlinJPoseyJTchekmedyianS2007Panitumumab with irino-tecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancerClin Colorectal Cancer64273217531105
   PubMed Web of Science ®Google Scholar
• BosJL1989ras Oncogenes in human cancer: a reviewCancer Res49468292547513
   PubMed Web of Science ®Google Scholar
• ChungKYShiaJKemenyNE2005Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryJ Clin Oncol2318031015677699
   PubMed Web of Science ®Google Scholar
• CitriAYardenY2006EGF-ERBB signalling: towards the systems levelNat Rev Mol Cell Biol75051616829981
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaS2004Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med3513374515269313
   PubMed Web of Science ®Google Scholar
• FearonERVogelsteinB1990A genetic model for colorectal tumorigenesisCell61759672188735
   PubMed Web of Science ®Google Scholar
• FoonKAYangXDWeinerLM2004Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInt J Radiat Oncol Biol Phys589849014967460
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEStellaP2007bAn interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab for metastatic colorectal cancerProceedings from the Ninth World Congress on Gastrointestinal CancerBarcelona, Spain
   Google Scholar
• HechtJRPatnaikABerlinJ2007aPanitumumab monotherapy in patients with previously treated metastatic colorectal cancerCancer110980817671985
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardE2008Cancer statistics, 2008CA Cancer J Clin58719618287387
   PubMed Web of Science ®Google Scholar
• JonkerDJO’CallaghanCJKarapetisCS2007Cetuximab for the treatment of colorectal cancerN Engl J Med3572040818003960
   PubMed Web of Science ®Google Scholar
• LenzHJVan CutsemEKhambata-FordS2006Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesJ Clin Oncol2449142117050875
   PubMed Web of Science ®Google Scholar
• MalikIHechtJRPatnaikA2005Safety and efficacy of panitu-mumab monotherapy in patients with metastatic colorectal cancer (mCRC) [abstract]J Clin Oncol (Meeting Abstracts)233520
   Google Scholar
• MendelsohnJ2002Targeting the epidermal growth factor receptor for cancer therapyJ Clin Oncol201S13S12235219
   PubMed Web of Science ®Google Scholar
• MitchellEPHechtJRBarandaJ2007Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis [abstract]J Clin Oncol (Meeting Abstracts)254082
   Google Scholar
• O’NeilBHAllenRSpigelDR2007High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyJ Clin Oncol253644817704414
   PubMed Web of Science ®Google Scholar
• PippasAWLenzHJMayerRJ2005Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy [abstract]J Clin Oncol (Meeting Abstracts)233595
   Google Scholar
• SaltzLBLenzHJKindlerHL2007Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 studyJ Clin Oncol2545576117876013
   PubMed Web of Science ®Google Scholar
• SaltzLBMeropolNJLoehrerPJSr2004Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptorJ Clin Oncol221201814993230
   PubMed Web of Science ®Google Scholar
• SobreroAFMaurelJFehrenbacherL2008EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancerJ Clin Oncol262311918390971
   PubMed Web of Science ®Google Scholar
• Van CutsemENowackiMLangI2007aRandomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial [abstract]J Clin Oncol (Meeting Abstracts)254000
   Google Scholar
• Van CutsemEPeetersMSienaS2007bOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol2516586417470858
   PubMed Web of Science ®Google Scholar
• WeinerLMBelldegrunARowinskyE2005Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies [abstract]J Clin Oncol (Meeting Abstracts)233059
   Web of Science ®Google Scholar
• YangXDJiaXCCorvalanJR2001Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCrit Rev Oncol Hematol38172311255078
   PubMed Web of Science ®Google Scholar